A basic insight into aptamer-drug conjugates (ApDCs). (November 2018)

• Record Type: Journal Article
• Authors: Xuan, Wenjing; Peng, Yongbo; Deng, Zhengyu; Peng, Tianhuan; Kuai, Hailan; Li, Yingying; He, Jiaxuan; Jin, Cheng; Liu, Yanlan; Wang, Ruowen; Tan, Weihong
• Is Part Of: Biomaterials. Volume 182(2018)
• Page Start: 216
• Page End: 226
• Publication Date: 2018-11
• Subjects: Aptamers -- Cell-SELEX -- Aptamer-drug conjugates (ApDCs) -- Targeted therapy; Biomedical materials -- Periodicals; Biocompatible Materials -- Periodicals; Biomatériaux -- Périodiques; 610.28
• DOI: 10.1016/j.biomaterials.2018.08.021
• Languages: English
• ISSNs: 0142-9612

Abstract

Abstract: Aptamers are often compared with antibodies since both types of molecules function as targeting ligands for specific cancer cell recognition. However, aptamers offer several advantages, including small size, facile chemical modification, high chemical stability, low immunogenicity, rapid tissue penetration, and engineering simplicity. Despite these advantages, several crucial factors have delayed their clinical translation, such as concerns over inherent physicochemical stability and safety. Meanwhile, steps have been taken to make aptamer-drug conjugates, or ApDCs, a clinically practical tool. In this review, we highlight the development of ApDCs and discuss how researchers are solving some problems associated with their clinical application for targeted therapy.